Fibromyalgia Pipeline Therapeutics and Drugs Market Review H1 2017

PUNE, India, June 7, 2017 /PRNewswire-iReach/ -- ReportsnReports.com added Fibromyalgia Pipeline Review H1 2017 report provides an overview of the Fibromyalgia pipeline landscape. Report provides comprehensive information on the therapeutics under development for Fibromyalgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Complete report on Fibromyalgia Pipeline Review H1 2017 spread across 62 pages is available at: http://www.reportsnreports.com/reports/911443-fibromyalgia-pipeline-review-h1-2017.html.

Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 6, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Companies Involved in Fibromyalgia Therapeutics Development Discussed - Astellas Pharma Inc, Daiichi Sankyo Company Ltd, Immune Therapeutics Inc, Innovative Med Concepts LLC, Jiangsu Hengrui Medicine Co Ltd, KPI Therapeutics Inc, Merck & Co Inc, Pfizer Inc, SWITCH Biotech LLC, Theravance Biopharma Inc, Vitality Biopharma Inc, Zynerba Pharmaceuticals Inc

Direct Purchase This Report at http://www.reportsnreports.com/purchase.aspx?name=911443.

Fibromyalgia Drug Profile Discussed - (celecoxib + famciclovir), AS-1069562, ASP-0819, ASP-8062, mirogabalin besylate, mirtazapine ODT, naltrexone hydrochloride, Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System, pregabalin CR, pregabalin SR, SWT-06101, TD-9855, U-2902, VB-210, ZYN-001, Zynerba Pharmaceuticals Inc.

Pharmaceutical and Healthcare latest pipeline guide Fibromyalgia – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibromyalgia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Related Report onFibromyalgia Epidemiology Available at:

Fibromyalgia - Epidemiology Forecast To 2023

Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Fibromyalgia in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Fibromyalgia prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Fibromyalgia . The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by team of industry experts.

About Us:

ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Media Contact:Ritesh Tiwari, ReportsnReports, +1-888-391-5441, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE ReportsnReports.com